◆ mixed
Impact
PhasePhase 1/2
Time to marketAt least 3-5 years. COM701 is in Phase 1/2 (MAIA trial); even with positive interim data in Q1 2027, a registrational Phase 3 trial and FDA review would follow, putting potential approval in the 2029-2031 timeframe.
COM701 anti-PVRIG monoclonal antibody Updated Aug 27
What to watch
The next hard catalyst for COM701 is the MAIA-ovarian interim PFS analysis expected by Q1 2027, roughly 4-6 months out. Positive data could drive a significant re-rating given the strong analyst consensus (10 Buy/Strong Buy vs 1 Hold) and ~41% implied upside to the $4.60 mean price target. Negative data would be a major setback for Compugen's wholly-owned pipeline. Monitor for any pre-announcements or delays.
Bull case
- COM701 targets a novel immune checkpoint (PVRIG) with a differentiated mechanism, potentially active in tumors resistant to PD-1 inhibitors.
- Strong analyst conviction: 10 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $4.60 (40.8% upside from $2.84).
- Cash runway into 2029 ($125.3M, no debt) eliminates near-term financing risk and allows the MAIA trial to reach its readout.
Bear case
- MAIA-ovarian interim PFS data (expected Q1 2027) could miss efficacy endpoints, wiping out the value of Compugen's wholly-owned lead asset.
- Elevated short-volume ratio (48-65% range over the past 90 days) indicates persistent bearish positioning and skepticism about the pipeline.
- Compugen has a $100M ATM facility that could dilute shareholders if cash burn accelerates before the COM701 readout.